ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2198

Genome Wide Association Meta-Analysis Implicates HLA-DRB1, The BTNL2/HLA-DRA region, and a Novel Susceptibility Locus On Chromosome 1 In Systemic Juvenile Idiopathic Arthritis

Michael J. Ombrello1, Elaine F. Remmers2, Ioanna Tachmazidou3, Alexei A. Grom4, Dirk Föll5, Alberto Martini6, Marco Gattorno7, Seza Ozen8, Sampath Prahalad9, John F. Bohnsack10, Norman T. Ilowite11, Elizabeth D. Mellins12, Ricardo A. G. Russo13, Claudio A. Len14, Sheila K. Oliveira15, Rae SM Yeung16, Lucy R. Wedderburn17, Jordi Anton18, Carl D. Langefeld19, Susan D. Thompson20, Eleftheria Zeggini3, Wendy Thomson21, Daniel L. Kastner22, Patricia Woo23 and on Behalf Of the International Childhood Arthritis Genetics Consortium24, 1Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 4Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, 6Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 7Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, 8Hacettepe University, Ankara, Turkey, 9Emory University School of Medicine, Atlanta, GA, 10Pediatriacs, University of Utah, Salt Lake City, UT, 11Pediatrics, Albert Einstein College of Medicine, Bronx, NY, 12Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, 13Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 14Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, 15PRINTO-Istituto Gaslini, Genova, Italy, 16Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 17Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 18Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, 19Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 20Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 21Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 22Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, 23University College London, London, United Kingdom, 24INCHARGE, London, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Still's disease, Systemic JIA and genomics

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory disease of childhood characterized by periods of daily spiking fever, evanescent skin rash, arthritis, serositis, lymphoid hyperplasia, and in up to half of cases, macrophage activation syndrome. The causes of sJIA are unknown, and the rare nature and complex inheritance of sJIA have together stymied the investigation of sJIA genetics.

Methods: To identify genetic factors contributing to sJIA susceptibility, we generated single nucleotide polymorphism (SNP) genotypes in 988 children with sJIA and 514 healthy control subjects using a commercially available SNP array. These data were combined with SNP genotypes, in silico, from 7370 additional healthy control subjects. After dividing the dataset into 9 strata by country of origin, we excluded samples and markers that failed to meet strict quality standards. Haplotype phasing, SNP imputation, and association testing were performed independently in each stratum, and we then subjected the association results from > 1.6M SNPs to fixed- and random-effects meta-analyses. A second round of more intensive imputation employing a more densely genotyped set of reference haplotypes was performed in each region with pmin < 1.0E-7. Regions with association signals exceeding genomewide significance (p < 1.7E-8) were further evaluated with logistic regression and conditional analysis.

Results: Genome wide meta-analysis of sJIA identified associations between sJIA and two regions, the major histocompatibility complex (MHC) locus and an intergenic region on chromosome 1, each of which were subjected to a second round of SNP imputation. In both regions, meta-analysis of the second round of imputation data identified significant associations. Meta-analyses of the MHC locus identified two strong association signals, the first centered around HLA-DRB1 (pmin = 1.6E-10, OR 1.5) and the second located between BTNL2 and HLA-DRA (pmin = 7.1E-15, OR 2.2). Reciprocal univariate regression demonstrated that these two markers likely represent independent sources of sJIA risk. On chromosome 1, we identified an sJIA-associated cluster of 9 SNPs (pmin = 5.4E-9, OR 2.0) that was nearest to LOC284661, encoding a long, intergenic noncoding RNA. By cross referencing data from the ENCODE project with the 9 sJIA associated SNPs, we found evidence of transcriptional activity across the sJIA-associated region and in close proximity to many of the sJIA-associated SNPs. Furthermore, several of the sJIA-associated SNPs were located within known histone marks or transcription factor binding sites.

Conclusion: Our data implicate the class II MHC molecule, HLA-DR, in the pathogenesis of sJIA. The intergenic location of the most strongly associated variants raises the possibility that an alteration of HLA-DR regulation or expression may underlie its role in sJIA.  Additionally, we have identified a novel genomic region on chromosome 1 as an sJIA susceptibility locus. Interestingly, the nearest gene encodes an uncharacterized long, intergenic noncoding RNA, a type of transcriptional regulator whose importance has only recently come to light.


Disclosure:

M. J. Ombrello,
None;

E. F. Remmers,
None;

I. Tachmazidou,
None;

A. A. Grom,
None;

D. Föll,
None;

A. Martini,

Abbott, AstraZeneca, BMS, Centocor, Lilly, Francesco Angelini, GSK, Italfarmaco, MerckSerono, Novartis, Pfizer, Regeneron, Roche, Sanofi Aventis, Schwarz Biosciences, Xoma, Wyeth,

2,

Abbott, AstraZeneca, BMS, Centocor, Lilly, Francesco Angelini, GSK, Italfarmaco, MerckSerono, Novartis, Pfizer, Regeneron, Roche, Sanofi Aventis, Schwarz Biosciences, Xoma, Wyeth,

5,

Abbott, Boehringer, BMS, Novartis, Astellas, Italfarmaco, MedImmune, Pfizer, Roche,

8;

M. Gattorno,
None;

S. Ozen,
None;

S. Prahalad,
None;

J. F. Bohnsack,
None;

N. T. Ilowite,
None;

E. D. Mellins,
None;

R. A. G. Russo,
None;

C. A. Len,
None;

S. K. Oliveira,

Novartis-Roche,

2;

R. S. Yeung,
None;

L. R. Wedderburn,
None;

J. Anton,

Research grant,

2,

Consulting fees ,

5,

Speakers’ bureau ,

8;

C. D. Langefeld,
None;

S. D. Thompson,
None;

E. Zeggini,
None;

W. Thomson,
None;

D. L. Kastner,
None;

P. Woo,
None;

O. B. O. the International Childhood Arthritis Genetics Consortium,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-meta-analysis-implicates-hla-drb1-the-btnl2hla-dra-region-and-a-novel-susceptibility-locus-on-chromosome-1-in-systemic-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology